Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results
Halozyme Therapeutics (NASDAQ: HALO) has announced it will release its fourth quarter and full year 2024 financial and operating results on Tuesday, February 18, 2025, after market close. The company will host a conference call the same day at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. Investors can access the call through pre-registration and view a live webcast through the investor section of Halozyme's website.
Halozyme Therapeutics (NASDAQ: HALO) ha annunciato che rilascerà i suoi risultati finanziari e operativi del quarto trimestre e dell'anno intero 2024 martedì 18 febbraio 2025, dopo la chiusura del mercato. L'azienda terrà una conference call lo stesso giorno alle 13:30 PT/16:30 ET per discutere i risultati. Gli investitori possono accedere alla chiamata tramite pre-registrazione e visualizzare una diretta streaming attraverso la sezione investitori del sito web di Halozyme.
Halozyme Therapeutics (NASDAQ: HALO) ha anunciado que publicará sus resultados financieros y operativos del cuarto trimestre y del año completo 2024 el martes 18 de febrero de 2025, después del cierre del mercado. La compañía realizará una conferencia telefónica el mismo día a la 1:30 p.m. PT/4:30 p.m. ET para discutir los resultados. Los inversores pueden acceder a la llamada mediante preinscripción y ver una transmisión en vivo a través de la sección de inversores del sitio web de Halozyme.
Halozyme Therapeutics (NASDAQ: HALO)는 2024년 4분기 및 연간 재무 및 운영 결과를 2025년 2월 18일 화요일 시장 종료 후 발표할 것이라고 발표했습니다. 회사는 결과를 논의하기 위해 같은 날 오후 1:30 PT/오후 4:30 ET에 컨퍼런스 콜을 개최할 것입니다. 투자자들은 사전 등록을 통해 콜에 접근할 수 있으며 Halozyme의 웹사이트 투자자 섹션에서 실시간 웹캐스트를 볼 수 있습니다.
Halozyme Therapeutics (NASDAQ: HALO) a annoncé qu'elle publiera ses résultats financiers et d'exploitation pour le quatrième trimestre et l'année complète 2024 le mardi 18 février 2025, après la clôture du marché. La société organisera une conférence téléphonique le même jour à 13h30 PT/16h30 ET pour discuter des résultats. Les investisseurs peuvent accéder à l'appel par préinscription et visionner un webinaire en direct via la section investisseurs du site Web de Halozyme.
Halozyme Therapeutics (NASDAQ: HALO) hat angekündigt, dass es seine Finanz- und Betriebsergebnisse für das vierte Quartal und das gesamte Jahr 2024 am Dienstag, dem 18. Februar 2025, nach Börsenschluss veröffentlichen wird. Das Unternehmen wird am selben Tag um 13:30 Uhr PT/16:30 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Investoren können über eine Vorabregistrierung auf den Anruf zugreifen und einen Live-Webcast über den Investorenbereich der Halozyme-Website ansehen.
- None.
- None.
Halozyme will host a conference call on Tuesday, February 18, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I7813760.
A live webcast and replay of the conference call will also be available through the "Investors" section of Halozyme's corporate website at www.halozyme.com.
About Halozyme
Halozyme is a biopharmaceutical company advancing disruptive solutions to improve patient experiences and outcomes for emerging and established therapies. As the innovators of ENHANZE® drug delivery technology with the proprietary enzyme rHuPH20, Halozyme's commercially-validated solution is used to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. Having touched one million patient lives in post-marketing use in nine commercialized products across more than 100 global markets, Halozyme has licensed its ENHANZE® technology to leading pharmaceutical and biotechnology companies including Roche, Takeda, Pfizer, Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical and Acumen Pharmaceuticals.
Halozyme also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies that are designed to provide commercial or functional advantages such as improved convenience, reliability and tolerability, and enhanced patient comfort and adherence. The Company has two commercial proprietary products, Hylenex® and XYOSTED®, partnered commercial products and ongoing product development programs with several pharmaceutical companies including Teva Pharmaceuticals and Idorsia Pharmaceuticals.
Halozyme is headquartered in
For more information visit www.halozyme.com and connect with us on LinkedIn and Twitter.
Contacts:
Tram Bui
VP, Investor Relations and Corporate Communications
609-333-7668
tbui@halozyme.com
Samantha Gaspar
Teneo
212-886-9356
samantha.gaspar@teneo.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/halozyme-to-report-fourth-quarter-and-full-year-2024-financial-and-operating-results-302367381.html
SOURCE Halozyme Therapeutics, Inc.
FAQ
When will Halozyme (HALO) release Q4 and full year 2024 earnings?
What time is Halozyme's (HALO) Q4 2024 earnings call?
How can investors access Halozyme's (HALO) Q4 2024 earnings call?
Will there be a replay available for Halozyme's (HALO) Q4 2024 earnings call?
